RAIKRA is a medication that is given to pregnant women who have a low thyroid hormone level. The medication helps to keep the thyroid hormone at a healthy level throughout the pregnancy.

It is critical for newborns to have adequate thyroid hormone levels, as it is essential for normal growth and development.

How RAIKRA Works

The thyroid gland is a small, butterfly-shaped gland located in the neck that produces hormones that regulate the metabolism of the body. The thyroid hormone is essential for normal growth and development.

During pregnancy, the thyroid hormone level can change, leading to complications for both the mother and the developing fetus.

RAIKRA is a medication that helps to keep the thyroid hormone at a healthy level throughout the pregnancy. The medication contains a synthetic form of the thyroid hormone known as levothyroxine sodium.

The medication is taken orally, and the dosage is adjusted based on the individual’s thyroid hormone levels and the stage of the pregnancy.

The Importance of Adequate Thyroid Hormone Levels in Newborns

Adequate thyroid hormone levels are critical for normal growth and development in newborns. The thyroid hormone plays a crucial role in the development of the brain, nervous system, and skeletal system.

Low thyroid hormone levels in newborns can lead to intellectual impairment, delayed growth, and developmental delays.

Thyroid hormone deficiency in newborns is a condition known as congenital hypothyroidism. The condition affects approximately 1 in every 2000-3000 newborns.

The condition is usually detected through newborn screening, which involves a blood test shortly after birth. Early detection and treatment of congenital hypothyroidism can prevent long-term complications and ensure normal growth and development.

The Safety of RAIKRA for Newborns

RAIKRA is considered safe for both the mother and the developing fetus when prescribed and monitored by a healthcare provider. The medication does not cross the placenta and therefore does not affect the developing fetus directly.

However, it is essential to monitor the mother’s thyroid hormone levels throughout the pregnancy to ensure the health of the developing fetus.

Studies have shown that RAIKRA does not increase the risk of congenital anomalies or other adverse outcomes in newborns.

The medication has been used safely for decades to treat hypothyroidism in pregnant women, and its use in pregnancy is well-documented.

The Risks of Untreated Hypothyroidism in Pregnancy

Untreated hypothyroidism in pregnancy can lead to a range of complications for both the mother and the developing fetus. The condition can increase the risk of miscarriage, premature birth, and low birth weight.

It can also lead to preeclampsia and postpartum hemorrhage in the mother.

Untreated hypothyroidism in pregnancy can also lead to developmental delays and intellectual impairment in the developing fetus.

The condition can affect the growth of the brain and nervous system, leading to long-term complications that can impact the child’s quality of life.

Conclusion

RAIKRA is a medication used to treat hypothyroidism in pregnant women. The medication helps to keep the thyroid hormone at a healthy level throughout the pregnancy, ensuring normal growth and development in the developing fetus.

Adequate thyroid hormone levels are critical for the development of the brain, nervous system, and skeletal system in newborns. Untreated hypothyroidism in pregnancy can lead to a range of complications for both the mother and the developing fetus. RAIKRA is considered safe for both the mother and the developing fetus when prescribed and monitored by a healthcare provider.